PMID- 29422962
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 1
DP  - 2018 Jan
TI  - Metformin and cancer: An existing drug for cancer prevention and therapy.
PG  - 683-690
LID - 10.3892/ol.2017.7412 [doi]
AB  - Metformin is a standard clinical drug used to treat type 2 diabetes mellitus 
      (T2DM) and polycystic ovary syndrome. Recently, epidemiological studies and 
      meta-analyses have revealed that patients with T2DM have a lower incidence of 
      tumor development than healthy controls and that patients diagnosed with cancer 
      have a lower risk of mortality when treated with metformin, demonstrating an 
      association between metformin and tumorigenesis. In vivo and in vitro studies 
      have revealed that metformin has a direct antitumor effect, which may depress 
      tumor proliferation and induce the apoptosis, autophagy and cell cycle arrest of 
      tumor cells. The mechanism underpinning the antitumor effect of metformin has not 
      been well established. Studies have demonstrated that reducing insulin and 
      insulin-like growth factor levels in the peripheral blood circulation may lead to 
      the inhibition of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin 
      (mTOR) signaling or activation of AMP-activated protein kinase, which inhibits 
      mTOR signaling, a process that may be associated with the antitumor effect of 
      metformin. The present review primarily focuses on the recent progress in 
      understanding the function of metformin in tumor development.
FAU - Zi, Fuming
AU  - Zi F
AD  - Department of Hematology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi 330008, P.R. China.
FAU - Zi, Huapu
AU  - Zi H
AD  - Department of Oncology, Rizhao Traditional Chinese Medicine Hospital of Shandong 
      Traditional Chinese Medicine University, Rizhao, Shandong 276800, P.R. China.
FAU - Li, Yi
AU  - Li Y
AD  - Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
FAU - He, Jingsong
AU  - He J
AD  - Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
FAU - Shi, Qingzhi
AU  - Shi Q
AD  - Department of Hematology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi 330008, P.R. China.
FAU - Cai, Zhen
AU  - Cai Z
AD  - Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20171114
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5772929
OTO - NOTNLM
OT  - cancer
OT  - diabetes
OT  - mechanisms
OT  - metformin
EDAT- 2018/02/10 06:00
MHDA- 2018/02/10 06:01
PMCR- 2017/11/14
CRDT- 2018/02/10 06:00
PHST- 2016/09/03 00:00 [received]
PHST- 2017/09/22 00:00 [accepted]
PHST- 2018/02/10 06:00 [entrez]
PHST- 2018/02/10 06:00 [pubmed]
PHST- 2018/02/10 06:01 [medline]
PHST- 2017/11/14 00:00 [pmc-release]
AID - OL-0-0-7412 [pii]
AID - 10.3892/ol.2017.7412 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Jan;15(1):683-690. doi: 10.3892/ol.2017.7412. Epub 2017 Nov 14.